In our study, the best patient outcome was seen in breast cancer patients with a moderate mammaglobin-A staining of their tumors, while the prognosis was slightly worse in tumors with weak or negative staining and worst in tumors with strong staining. The gene discussed is SCGB2A2; the disease is breast cancer.